Daxor (NASDAQ:DXR) Given New $24.75 Price Target at Ascendiant Capital Markets

Daxor (NASDAQ:DXR) had its price objective raised by Ascendiant Capital Markets from $24.50 to $24.75 in a research report report published on Monday, Marketbeat.com reports. The firm currently has a buy rating on the stock.

Daxor Stock Down 3.6 %

NASDAQ:DXR opened at $9.14 on Monday. The stock’s 50-day simple moving average is $8.83 and its 200 day simple moving average is $8.95. Daxor has a 52-week low of $7.11 and a 52-week high of $10.04.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.